American students progress toward proficiency in mathematics requires major changes in instruction, curricula, and assessment in the nations schools, says a new report from the National Research Council of the National Academies.

Infectious disease outbreaks that turn into epidemics or pandemics can kill millions of people and cause trillions of dollars of damage to economic activity, says a new report from the international, independent Commission on a Global Health Risk Framework for the Future.

While scientists have made remarkable advancements in astronomy and astrophysics since the beginning of this decade – notably the first detection of gravitational waves and the discovery of distant Earth-like planets – unforeseen constraints have slowed progress toward reaching some of the priorities and goals outlined in the Academies’ 2010 decadal survey of these disciplines, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine offers detailed recommendations to guide federal statistical agencies in creating a new entity that would enable them to combine data from multiple sources in order to provide more relevant, timely, and detailed statistics – for example, on the unemployment rate or the rate of violent crime.

Producing more precise county-level estimates of crops and farmland cash rents will require integrating multiple data sources using model-based predictions that are more transparent and reproducible, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The supercritical water oxidation (SCWO) system is a secondary waste processing reactor of the Blue Grass Chemical Agent Destruction Pilot Plant (BGCAPP). It is perhaps second in importance behind the agent neutralization reactors, which perform base hydrolysis of chemical warfare agents stored at the Blue Grass Army Depot.

The National Academies today released Criteria for Selecting the Leading Health Indicators for Healthy People 2030, the first of two reports that will help inform the development of Healthy People 2030 (HP2030).

When Sara Altschule took a 23andMe ancestry test, the results confirmed what she already suspected - She is 77 percent Ashkenazi Jewish.

The opioid epidemic in the U.S. is driving a simultaneous epidemic of infectious diseases — including HIV, hepatitis C virus (HCV) and bacterial infections, and sexually transmitted infections — but workforce shortages, stigma, and financial and policy barriers are preventing the integration of opioid use disorder (OUD) and infectious disease services, says a new report from the National Academies of Sciences, Engineering, and Medicine.

NASA, NSF, and NOAA have made substantial progress in implementing the programs recommended in the 2013 decadal survey on solar and space physics (heliophysics) despite a challenging budgetary landscape, says a new midterm assessment from the National Academies of Sciences, Engineering, and Medicine.

From N-95 masks that are protecting health care workers during the COVID-19 pandemic to food packaging found in every aisle of the grocery store, plastics play an essential role in our lives.

US-based payments processor Nets has released

Patt Morrison's ensemble for Aug 8, 2013.; Credit: Dave Coelho/KPCC

What shall we call this color scheme? How about ‘Manhattan Mermaid’?

The petrel blues, the turquoises, the aquas – and then that uptown/downtown black, in this case a black linen duster over a Peter Max-style splashy-print silk dress. The way the hem pools at the sides a bit reminds me of the cut of Pre-Raphaelite ladies’ tunics; I’d love to dress “period” for a week to see whether I’d like it.

Imagine, a week of hoop skirts … a week of 1950s tailleurs … a week of bustles … a week of hobble skirts … a week of liberated Pre-Raphaelite velvet gowns!

The hat is so unmistakably summer in fabric and color that it doesn’t get out of the hatbox as much as it should, poor thing. And the shoes – I did not get them together, honest, but even though the prints don’t match, it’s the dissonance that makes them work better together than if they had.

The fabric is a very textured canvas and printed like batik. [They are not the soul of comfort – oh what a dreadful pun, but is there any other kind of pun? – but they look smart hooked over the railing of a chair in a chic bistro, which is where I intend to take them!]

And the bracelets, one from a great-aunt who had a fine eye for jewelry – the turquoise is almost Persian, it’s so green, but it’s more likely to be American. The cuff is definitely Southwest, with the rope-pattern trim and the irregularly shaped bezels, although the turquoises themselves are symmetrical.

Because I’m left-handed, my right arm bears the singular honor of being “ornamental,” and bearing the burden of the bling.

Summer on, ladies!

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Organisations are increasingly applying green business principles. According to a recent study, electronics manufacturing companies in Taiwan that practice green supply chain management (GSCM) have a better business performance than companies that do not. Those with a strong green marketing focus performed the best, successfully competing with their rivals.

A new study has shed light on the sustainable credentials of bio-based plastics. It indicates that, as yet, no bio-based plastics are sustainable, owing to practices including pesticide use. However, this could change with further technological development.

Geography and ecology are key factors that have influenced the genetic makeup of human groups in southern Africa, according to new research discussed in the journal GENETICS, a publication of the Genetics Society of America. By investigating the ancestries of twenty-two KhoeSan groups, including new samples from the Nama and the ≠Khomani, researchers conclude that the genetic clustering of southern African populations is closely tied to the ecogeography of the Kalahari Desert region.

read more

The study, published today in Nature Microbiology, holds promise for a new treatment method against antibiotic-resistant bacteria (commonly known as superbugs).

read more

Widespread use of antibiotics to prevent and treat infections in people and animals as well as for promoting growth in livestock is causing environmental contamination. A new study highlights the need for extra measures to reduce environmental pollution from antibiotics. Such pollution can increase the risk of diseases caused by bacteria that become resistant to antibiotics.

The presence of plastics in aquatic environments is a growing concern across the EU. This study explored the amount of microplastic particles present in raw and treated water at three water-treatment plants in the Czech Republic. While treated water contained fewer particles than raw1 fresh water, the amount found in treated water was not negligible, and largely comprised tiny particles of <10 micrometres (μm) in diameter. Ways to filter microplastics from potable water must be identified and their risk to humans, sources and routes into drinking water determined, say the researchers.

Biodegradable plastics that break down in the environment can be used instead of traditional plastics to reduce the problem of plastic waste disposal. A new study highlights large differences in the rates of decomposition of these polymers, which can affect decisions on disposal methods.

Plastic debris is a serious environmental concern, as a physical pollutant as well as a chemical pollutant when it breaks down in the marine environment. A new study has now shown that plastics can also concentrate other pollutants, with significantly higher concentrations of toxic pollutants adhering to soft, rubbery plastics, rather than hard, glassy plastics.

Composts containing biodegradable plastics may hinder rather than help plant growth, according to a recent study by university scientists in Poland. These findings have implications for waste management practices within the EU.

Oysters exposed to polystyrene microplastics produced fewer offspring, which were also smaller and slower growing than offspring from unexposed oysters, according to recent research. The researchers say their study adds to growing evidence of the harm caused by microplastic pollution and can help stakeholders to take action on plastic debris entering the oceans to limit its long-term impact on marine life.

A successful circular economy for valuable metals needs more than just effective recycling technologies, as a new study shows. The research, which explored the governance of recovering vanadium from steel-industry waste, revealed that industry stakeholders feel the prospect of financial gain, or reduced costs, through recovery is too distant at present. This perception could hinder a circular economy for critical materials from industrial residue, the study warns.

Scientists have tested the behaviour of biodegradable plastics in managed composting and anaerobic conditions, as well as under simulated environmental conditions, such as in seawater or soil. This study found that blending different types of biodegradable plastics may open up new opportunities in relation to their end-of-life treatment — notably the potential to make one of the world’s best-selling biodegradable plastics, polyactic acid (PLA), home-compostable by blending it with another polymer (polycaprolactone — PCL). However, the researchers were also concerned that most materials tested could still cause plastic pollution as they failed to biodegrade sufficiently — and, in some cases, not at all, in particular, in soil and the marine environment.

Between 13% and 16% of waste electric and electronic equipment (WEEE), furniture and leisure goods disposed of at household waste collection centres are in excellent working condition and could be easily be prepared for re-use, finds a new study from Bavaria, Germany. Improvements to waste collection, storage and treatment practices to prevent damage to disposed items could free up a further 13%-29% of these waste streams for re-use. Notably, weatherproof storage for WEEE at collection points could have prevented up to 86% of the damage endured by the studied items.

Simple characteristics of plant species - such as height or leaf size - can be used to predict the ecosystem services provided by the green roofs they grow on, a new study suggests. The researchers suggest that their method could be used to screen the thousands of potential plant species in order to optimize green roof design.

Using vegetable waste to produce bioplastics can provide sustainable alternatives to non-biodegradable plastic, new research has found. The biodegradable plastic developed for this study, produced using parsley and spinach stems, cocoa pod husks and rice hulls, have a range of mechanical properties comparable to conventional plastics which are used for products from carrier bags to kitchenware and computer components.

Erratum
This article was amended 10.12.14 to give more information about the nature of trifluoroacetic acid.

Identifying emerging research areas and technologies is important for decision makers, but notoriously difficult to do. This study presents a new way of searching the literature to identify emerging topics, which will help policymakers, industry and funding bodies to make better decisions.

For children with autism and a class of genetic disorders, exposure to diagnostic ultrasound in the first trimester of pregnancy is linked to increased autism severity, according to a study by researchers at UW Medicine, UW Bothell and Seattle Children's Research Institute.

read more

5G will cover more than 20 percent of the global population six years from now, according to the latest Ericsson Mobility Report

As electronics manufacturers are set to resume operations in India, it is apparent that in the short term there is no alternative to sourcing from China, as urgent replenishment of inventories clearly implies continued dependence on it.

Tiny plastic particles from laundry wastewater are being washed into the marine environment, according to recent research. The plastic, from synthetic clothes cleaned in domestic washing machines, is a significant source of contamination and, unless measures are taken to address the problem, growing coastal populations will only exacerbate the situation.

Samsung has created an ecommerce platform in partnership with Benow.in along with mobile phone retailers across the country that will allow them to sell and deliver smartphones. Offline stores are also being used to fulfil orders placed on Samsung’s e-store for television and appliances.

As part of the partnership with the Guiyang Municipal government, agreements worth 25 million Yen between Chinese customers and Indian service providers are also going to be announced.

Big infrastructure and cost requirements have long kept data analytics a fiefdom of large enterprises; however, the advent of cloud tech has made it possible for SMEs to use data analytics with a fraction of a cost.

Changing user consumption patterns and rapid adoption of omni-channel models drive demand.

With the release of the IoT analytics platform - Ginjer 2.0, SenRa is now able to provide customers with end-to-end IoT solutions while facilitating them with immediate insights on their business operations, cost savings, and overall ROI.

While Edge data centers will be providing an array of services independently, a more centralized data center can be backing them up with cloud services and analytics.

Analytics allows firms to see the full picture that’s painted when all the data sources come together.

The insurance firm is looking at ways to expand the business, improve claim processing by going deeper into machine learning and neural networks.